SLS Stock: Price, Earnings History and SEC Filings
SELLAS Life Sciences Group, Inc. (SLS) last traded at $9.68, down 4.72% on the latest session and down 21.4% over the past month.
$9.68 -4.72%
1 month-21.36%
52-week high$15.88
52-week low$1.39
Volume6.26M
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SLS earnings history
Earnings history is not available right now.
SLS financial history
Revenue
Net income
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2023 | $0 | -$37M | – | – | $-1.34 |
| 2022 | $1M | -$41M | – | -4130.1% | $-2.13 |
| 2021 | $8M | -$21M | – | -272.4% | $-1.34 |
| 2020 | $2M | -$17M | – | -881.9% | $-2.11 |
| 2019 | $0 | -$19M | – | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for SLS
SEC filing data is not available right now. You can search for SLS on SEC EDGAR.
SLS news
- SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3Oct 30, 2026 · stocktwits.com
- SELLAS Life Sciences Group (SLS) Dropped, So What Is Behind The Latest Attention?Oct 29, 2026 · finance.yahoo.com
- SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?Oct 29, 2026 · stocktwits.com
- Sellas’ GPS Trial Records 80th Event — Retail Says ‘Completely Irrational Sell Off’ As SLS Stock Tanks 18%Oct 28, 2026 · stocktwits.com
- Sellas Sinks 18% as Phase 3 Leukemia Trial Reaches “Critical Milestone” Ahead of Final DataOct 28, 2026 · tikr.com
- SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid LeukemiaOct 28, 2026 · finance.yahoo.com
- SLS Stock Gets A BlackRock Spotlight Ahead Of Phase 3 AML Data — Bulls Spot 2027 European GPS Approval ForecastOct 28, 2026 · stocktwits.com
- SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 YearsOct 20, 2026 · stocktwits.com
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (SLS) is a US-listed public company on Nasdaq.